Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
NCT07197671
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Cancer
Interventions
DRUG:
90Y-NM600
Sponsor
University of Wisconsin, Madison
Collaborators
[object Object]
[object Object]